Dimed Distribuidora de Medicamentos (BSP:PNVL3) Piotroski F-Score: 6 (As of Jun. 28, 2026) — Near Median


BSP:PNVL3 Dimed SA Distribuidora de Medicamentos BSP:PNVL3
88 GF Score
Price R$11.34
GF Value R$13.48
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Dimed Distribuidora de Medicamentos Piotroski F-Score?

Dimed Distribuidora de Medicamentos BSP:PNVL3 +0.35% 88 Piotroski F-Score is 6 as of Jun. 28, 2026, which is at its 10-year median of 6.00. GuruFocus rates BSP:PNVL3 with a GF Score™ of 88/100 and a GF Value™ of R$13.48 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 981 Drug Manufacturers companies, Dimed Distribuidora de Medicamentos ranks better than 79.2% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Dimed Distribuidora de Medicamentos has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Dimed Distribuidora de Medicamentos's Piotroski F-Score or its related term are showing as below:

BSP:PNVL3' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Dimed Distribuidora de Medicamentos was 8. The lowest was 4. And the median was 6.

Dimed Distribuidora de Medicamentos  (BSP:PNVL3) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Dimed Distribuidora de Medicamentos Piotroski F-Score Related Terms


Dimed Distribuidora de Medicamentos Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Dimed Distribuidora de Medicamentos's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimed Distribuidora de Medicamentos Piotroski F-Score Chart

Dimed Distribuidora de Medicamentos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 5.00 6.00 8.00

Dimed Distribuidora de Medicamentos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 7.00 7.00 8.00 6.00

BSP:PNVL3 vs LLY, JNJ, ABBV: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dimed Distribuidora de Medicamentos Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Dimed Distribuidora de Medicamentos's Piotroski F-Score falls into.


BSP:PNVL3
88GF Score
Dimed SA Distribuidora de Medicamentos BSP:PNVL3
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 25.09 + 31.302 + 42.747 + 33.231 = R$132 Mil.
Cash Flow from Operations was 121.666 + 125.027 + 126.785 + 77.29 = R$451 Mil.
Revenue was 1313.746 + 1373.996 + 1565.688 + 1449.661 = R$5,703 Mil.
Gross Profit was 433.505 + 447.035 + 502.883 + 380.688 = R$1,764 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3174.997 + 3326.445 + 3583.121 + 3830.51 + 3663.514) / 5 = R$3515.7174 Mil.
Total Assets at the begining of this year (Mar25) was R$3,175 Mil.
Long-Term Debt & Capital Lease Obligation was R$1,117 Mil.
Total Current Assets was R$2,145 Mil.
Total Current Liabilities was R$1,184 Mil.
Net Income was 5.13 + 35.858 + 30.971 + 25.466 = R$97 Mil.

Revenue was 1133.521 + 1236.065 + 1346.773 + 1258.688 = R$4,975 Mil.
Gross Profit was 363.411 + 390.041 + 423.803 + 401.095 = R$1,578 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(3204.298 + 3146.677 + 3232.719 + 3377.453 + 3174.997) / 5 = R$3227.2288 Mil.
Total Assets at the begining of last year (Mar24) was R$3,204 Mil.
Long-Term Debt & Capital Lease Obligation was R$961 Mil.
Total Current Assets was R$1,788 Mil.
Total Current Liabilities was R$941 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Dimed Distribuidora de Medicamentos's current Net Income (TTM) was 132. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Dimed Distribuidora de Medicamentos's current Cash Flow from Operations (TTM) was 451. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=132.37/3174.997
=0.04169138

ROA (Last Year)=Net Income/Total Assets (Mar24)
=97.425/3204.298
=0.03040448

Dimed Distribuidora de Medicamentos's return on assets of this year was 0.04169138. Dimed Distribuidora de Medicamentos's return on assets of last year was 0.03040448. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Dimed Distribuidora de Medicamentos's current Net Income (TTM) was 132. Dimed Distribuidora de Medicamentos's current Cash Flow from Operations (TTM) was 451. ==> 451 > 132 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1117.245/3515.7174
=0.31778578

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=961.197/3227.2288
=0.29783974

Dimed Distribuidora de Medicamentos's gearing of this year was 0.31778578. Dimed Distribuidora de Medicamentos's gearing of last year was 0.29783974. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2145.465/1184.327
=1.81154782

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1788.283/940.753
=1.90090598

Dimed Distribuidora de Medicamentos's current ratio of this year was 1.81154782. Dimed Distribuidora de Medicamentos's current ratio of last year was 1.90090598. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Dimed Distribuidora de Medicamentos's number of shares in issue this year was 149.975. Dimed Distribuidora de Medicamentos's number of shares in issue last year was 150.228. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1764.111/5703.091
=0.30932542

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1578.35/4975.047
=0.31725328

Dimed Distribuidora de Medicamentos's gross margin of this year was 0.30932542. Dimed Distribuidora de Medicamentos's gross margin of last year was 0.31725328. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=5703.091/3174.997
=1.79625083

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=4975.047/3204.298
=1.55261683

Dimed Distribuidora de Medicamentos's asset turnover of this year was 1.79625083. Dimed Distribuidora de Medicamentos's asset turnover of last year was 1.55261683. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+0+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Dimed Distribuidora de Medicamentos has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a Piotroski F-Score of 6 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Dimed Distribuidora de Medicamentos and its competitors. This is near median its historical median of 6.00. Over the past decade, Dimed Distribuidora de Medicamentos' Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #204 out of 981 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Dimed Distribuidora de Medicamentos' Piotroski F-Score too high?
Dimed Distribuidora de Medicamentos' current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Dimed Distribuidora de Medicamentos' value of 6 is 20% above this industry median. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #204 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' Piotroski F-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #204 out of 981 companies for Piotroski F-Score. This places Dimed Distribuidora de Medicamentos in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Dimed Distribuidora de Medicamentos' value of 6 is 20% above this benchmark. Historically, Dimed Distribuidora de Medicamentos' own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Dimed Distribuidora de Medicamentos has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimed Distribuidora de Medicamentos's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Dimed Distribuidora de Medicamentos and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.48, compared to a current price of R$11.34 — trading 15.9% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Drug Manufacturers industry median of 5.00. Dimed Distribuidora de Medicamentos' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current Piotroski F-Score is 6 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?

Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued. The current stock price of R$11.34 is trading 15.9% below its estimated GF Value™ of R$13.48. GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.

Key valuation signals for BSP:PNVL3:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: R$13.48 vs. price of R$11.34 (15.9% below fair value)
  • GF Score™: 88/100 with 5 warning signs
  • Industry Position: 20% above the Drug Manufacturers median (#204 of 981)

No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dimed Distribuidora de Medicamentos Business Description

Address Avenida Industrial Belgraf, 865, Eldorado do Sul, RS, BRA, 92990-000
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
88GF Score

Get the complete analysis for BSP:PNVL3

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$11.34
Price
R$13.48
GF Value